Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis

Journal of Hepatology

Volumn 53, Issue 3, 2010, Pages 542-550

  Anstee, Quentin M ^a   Concas, Danilo ^a   Kudo, Hiromi ^a   Levene, Adam ^a   Pollard, John ^b   Charlton, Peter ^b   Thomas, Howard C ^a   Thursz, Mark R ^a   Goldin, Robert D ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

Apoptosis; Fatty liver; Inflammation; NASH; Steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; CASPASE; CASPASE 3; CASPASE INHIBITOR; CHOLINE; CYCLINE; CYTOKERATIN 18; MACROGOL; METHIONINE; UNCLASSIFIED DRUG; VX 166;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FATTY LIVER; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY INFILTRATE; INTESTINE FLORA; INTESTINE MUCOSA; LIVER HISTOLOGY; LIVER INJURY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CASPASES; CHOLINE DEFICIENCY; CYSTEINE PROTEINASE INHIBITORS; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY LIVER; HUMANS; MALE; METHIONINE; MICE; MICE, INBRED C3H; MICE, OBESE; OXIDATIVE STRESS;

EID: 77955852465     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.03.016     Document Type: Article

References (37)

1. C.P. Day, and O.F. James Steatohepatitis: a tale of two "hits"? Gastroenterology 114 1998 842 845
2. Q.M. Anstee, and R.D. Goldin Mouse models in non-alcoholic fatty liver disease and steatohepatitis research Int J Exp Pathol 87 2006 1 16
3. H. Malhi, and G.J. Gores Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease Semin Liver Dis 28 2008 360 369
4. H. Malhi, G.J. Gores, and J.J. Lemasters Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 43 2006 S31 S44
5. G.C. Farrell, C.Z. Larter, J.Y. Hou, R.H. Zhang, M.M. Yeh, and J. Williams Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression J Gastroenterol Hepatol 24 2009 443 452
6. A.E. Feldstein, A. Canbay, P. Angulo, M. Taniai, L.J. Burgart, and K.D. Lindor Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis Gastroenterology 125 2003 437 443
7. A.E. Feldstein, A. Canbay, M.E. Guicciardi, H. Higuchi, S.F. Bronk, and G.J. Gores Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice J Hepatol 39 2003 978 983
8. A. Wieckowska, N.N. Zein, L.M. Yerian, A.R. Lopez, A.J. McCullough, and A.E. Feldstein In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease Hepatology 44 2006 27 33
9. S.W. Tait, and D.R. Green Caspase-independent cell death: leaving the set without the final cut Oncogene 27 2008 6452 6461
10. F. Martinon, and J. Tschopp Inflammatory caspases and inflammasomes: master switches of inflammation Cell Death Differ 14 2007 10 22
11. P. Weber, P. Wang, S. Maddens, P. Wang, R. Wu, and M. Miksa VX-166: a novel potent small molecule caspase inhibitor as a potential therapy for sepsis Crit Care 13 2009 R146
12. R.P. Witek, W.C. Stone, F.G. Karaca, W.K. Syn, T.A. Pereira, and K.M. Agboola Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis Hepatology 50 2009 1421 1430
13. J.F. Cobbold, Q.M. Anstee, R.D. Goldin, H.R. Williams, H.C. Matthews, and B.V. North Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue Clin Sci (Lond) 116 2009 403 413
14. A. Sahai, P. Malladi, X. Pan, R. Paul, H. Melin-Aldana, and R.M. Green Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin Am J Physiol Gastrointest Liver Physiol 287 2004 G1035 G1043
15. D.E. Kleiner, E.M. Brunt, M. Van Natta, C. Behling, M.J. Contos, and O.W. Cummings Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321
16. W.R. Duan, D.S. Garner, S.D. Williams, C.L. Funckes-Shippy, I.S. Spath, and E.A. Blomme Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts J Pathol 199 2003 221 228
17. ABI-Biosystems. User bulletin #2 ABI PRISM 7700 sequence detection system. ABI Biosystems, Inc.; 1997.
18. R.M. Ramalho, H. Cortez-Pinto, R.E. Castro, S. Sola, A. Costa, and M.C. Moura Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis Eur J Gastroenterol Hepatol 18 2006 21 29
19. A. Cauwels, B. Janssen, A. Waeytens, C. Cuvelier, and P. Brouckaert Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2 Nat Immunol 4 2003 387 393 (Pubitemid 36432323)
20. A.E. Feldstein, N.W. Werneburg, A. Canbay, M.E. Guicciardi, S.F. Bronk, and R. Rydzewski Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway Hepatology 40 2004 185 194
21. P. Vandenabeele, T. Vanden Berghe, and N. Festjens Caspase inhibitors promote alternative cell death pathways Sci STKE 2006 2006 pe44
22. A. Koteish, and A.M. Diehl Animal models of steatosis Semin Liver Dis 21 2001 89 104
23. A. Guilherme, G.J. Tesz, K.V. Guntur, and M.P. Czech Tumor necrosis factor-alpha induces caspase-mediated cleavage of peroxisome proliferator-activated receptor gamma in adipocytes J Biol Chem 284 2009 17082 17091
24. A. Canbay, A. Feldstein, E. Baskin-Bey, S.F. Bronk, and G.J. Gores The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse J Pharmacol Exp Ther 308 2004 1191 1196
25. P. Mofrad, M.J. Contos, M. Haque, C. Sargeant, R.A. Fisher, and V.A. Luketic Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values Hepatology 37 2003 1286 1292
26. J.P. Iredale, R.C. Benyon, J. Pickering, M. McCullen, M. Northrop, and S. Pawley Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors J Clin Invest 102 1998 538 549
27. J.P. Iredale Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ J Clin Invest 117 2007 539 548
28. Q.M. Anstee, R.D. Goldin, M. Wright, A. Martinelli, R. Cox, and M.R. Thursz Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies J Thromb Haemost 6 2008 1336 1343
29. N.P. Chalasani, A.J. Sanyal, K.V. Kowdley, P.R. Robuck, J. Hoofnagle, and D.E. Kleiner Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design Contemp Clin Trials 30 2009 88 96
30. A.J. Sanyal, N. Chalasani, K.V. Kowdley, A. McCullough, A.M. Diehl, and N.M. Bass Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 2010 1675 1685
31. J.S. Soden, M.W. Devereaux, J.E. Haas, E. Gumpricht, R. Dahl, and J. Gralla Subcutaneous vitamin E ameliorates liver injury in an in vivo model of steatocholestasis Hepatology 46 2007 485 495
32. I. Hickman, and G. Macdonald Is vitamin E beneficial in chronic liver disease? Hepatology 46 2007 288 290
33. J. Chirife, L. Herszage, A. Joseph, J.P. Bozzini, N. Leardini, and E.S. Kohn In vitro antibacterial activity of concentrated polyethylene glycol 400 solutions Antimicrob Agents Chemother 24 1983 409 412
34. M.J. Henry-Stanley, and C.L. Wells Polyethylene glycol influences microbial interactions with intestinal epithelium Shock 31 2009 390 396
35. S.Q. Yang, H.Z. Lin, M.D. Lane, M. Clemens, and A.M. Diehl Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis Proc Natl Acad Sci USA 94 1997 2557 2562
36. P.D. Cani, R. Bibiloni, C. Knauf, A. Waget, A.M. Neyrinck, and N.M. Delzenne Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice Diabetes 57 2008 1470 1481
37. M.E. Dumas, R.H. Barton, A. Toye, O. Cloarec, C. Blancher, and A. Rothwell Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice Proc Natl Acad Sci USA 103 2006 12511 12516